The NCI Genomic Data Commons as an engine for precision medicine

Blood

Volumn 130, Issue 4, 2017, Pages 453-459

  Jensen, Mark A ^a   Ferretti, Vincent ^b   Grossman, Robert L ^c   Staudt, Louis M ^d  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^c UNIVERSITY OF CHICAGO   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME;

CANCER RESEARCH; HEMATOLOGIC MALIGNANCY; HIGH THROUGHPUT SEQUENCING; HUMAN; MALIGNANT NEOPLASM; MEDICAL DOCUMENTATION; NATIONAL HEALTH ORGANIZATION; ONCOLOGIST; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PRIVACY; REVIEW; SOMATIC MUTATION; TREATMENT RESPONSE; TUMOR GENE; GENETIC DATABASE; GENETICS; NEOPLASM; SOFTWARE; UNITED STATES;

DATABASES, GENETIC; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; PRECISION MEDICINE; SOFTWARE; UNITED STATES;

EID: 85026324739     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-03-735654     Document Type: Review

References (39)

1. Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153(1):17-37.
2. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015; 21(8):922-926.
3. Dang L, Su SM. Isocitrate dehydrogenase mutation and (R)-2-hydroxyglutarate: from basic discovery to therapeutics development [published online ahead of print 3 April 2017]. Annu Rev Biochem. doi:10.1146/annurev-biochem-061516-044732.
4. Stein EM, Fathi AT, DiNardo CD, et al. Enasidenib (AG-221), a potent oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzyme, induces hematologic responses in patients with myelodysplastic syndromes (MDS) [abstract]. Blood. 2016;128(22). Abstract 343.
5. Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33(27): 2938-2948.
6. National Cancer Institute. Cancer Moonshot Blue Ribbon Panel. https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel. Accessed 2 May 2017.
7. Siu LL, Lawler M, Haussler D, et al. Facilitating a culture of responsible and effective sharing of cancer genome data. Nat Med. 2016;22(5):464-471.
8. National Institutes of Health. Genomic Data Sharing (GDS). https://gds.nih.gov/. Accessed 2 May 2017.
9. National Cancer Institute. Genomic Data Sharing (GDS) Policy. https://www.cancer.gov/grantstraining/grants-management/nci-policies/ genomic-data. Accessed 2 May 2017.
10. National Cancer Institute. Significant expansion of data available in the Genomic Data Commons. https://www.cancer.gov/news-events/pressreleases/2016/gdc-data-expansion-fmi. Accessed 2 May 2017.
11. Multiple Myeloma Research Foundation. The MMRF CoMMpass Study. https://www.themmrf.org/research-partners/mmrf-data-bank/ commpass-study/. Accessed 2 May 2017.
12. American Association for Cancer Research. AACR Project GENIE (Genomics Evidence Neoplasia Information Exchange). http://www.aacr.org/research/research/pages/aacr-project-genie.aspx. Accessed 2 May 2017.
13. Morgan M, Davis SR. GenomicDataCommons: a bioconductor interface to the NCI Genomic Data Commons [published online ahead of print on 4 April 2017]. bioRxiv. doi:10.1101/117200.
14. Broad Institute. GDCtools. https://github.com/broadinstitute/gdctools. Accessed 2 May 2017.
15. National Cancer Institute. Democratizing Access to CCG Data: Cancer Genomics Cloud Pilots. https://www.cancer.gov/about-nci/organization/ccg/blog/2017/cloud-pilots-democratize-data. Accessed 2 May 2017.
16. National Cancer Institute Genomic Data Commons. Requesting Data Submission. https://gdc.cancer.gov/node/633/. Accessed 2 May 2017.
17. National Cancer Institute Genomic Data Commons. Obtaining Access to Submit Data. https://gdc.cancer.gov/submit-data/obtainingaccess-submit-data. Accessed 2 May 2017.
18. National Cancer Institute Genomic Data Commons. Data Types and File Formats. https://gdc.cancer.gov/about-data/data-types-and-file-formats. Accessed 2 May 2017.
19. Ewing AD, Houlahan KE, Hu Y, et al; ICGC-TCGA DREAM Somatic Mutation Calling Challenge participants. Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection. Nat Methods. 2015; 12(7):623-630.
20. Fan Y, Xi L, Hughes DS, et al. MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data. Genome Biol. 2016;17(1):178.
21. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213-219.
22. Larson DE, Harris CC, Chen K, et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics. 2012;28(3):311-317.
23. Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3): 568-576.
24. National Cancer Institute Genomic Data Commons. Variant Calling at the GDC. https://gdc.cancer.gov/node/158/. Accessed 2 May 2017.
25. National Cancer Institute. CCG Welcomes a New Genomic Data Analysis Network. https://www.cancer.gov/about-nci/organization/ccg/blog/2016/ new-genomic-data-analysis-network. Accessed 2 May 2017.
26. US Department of Health and Human Services. Guidance Regarding Methods for De-identification of Protected Health Information in Accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. https://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/de-identification/index.html. Accessed 2 May 2017.
27. National Cancer Institute Genomic Data Commons. The GDC Application Programming Interface (API): An Overview. https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/. Accessed 2 May 2017.
28. National Cancer Institute Genomic Data Commons. GDC Data Transfer Tool. https://gdc.cancer.gov/access-data/gdc-data-transfer-tool. Accessed 2 May 2017.
29. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-404.
30. Forbes SA, Beare D, Boutselakis H, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45(D1): D777-D783.
31. Weston BW, Hayden MA, Roberts KG, et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol. 2013; 31(25):e413-e416.
32. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505(7484):495-501.
33. Puente XS, Beà S, Valdés-Mas R, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526(7574):519-524.
34. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015; 526(7574):525-530.
35. Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al; Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22): 2059-2074.
36. Farrar JE, Schuback HL, Ries RE, et al. Genomic profiling of pediatric acute myeloid leukemia reveals a changing mutational landscape from disease diagnosis to relapse. Cancer Res. 2016; 76(8):2197-2205.
37. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005-1015.
38. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181-185.
39. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360): 298-303.